Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Mariel Metcalfe
  • February 8, 2017
  • News

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US, France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.

The report is intended to help pharmaceutical companies with products in this disease area get a deeper understanding of patient attitudes to SLE and the impact it has on patients’ lives, attitudes to SLE treatment, as well as discuss unmet needs in all-round care.

Living with SLE is just one in a series of reports offering comprehensive insight into the chronic disease patient journey from pre-diagnosis to stabilisation. Living with Crohn’s (EU & US), Chronic Pain (US), Rheumatoid Arthritis (EU & US), PsA (EU) and Ulcerative Colitis (EU) reports have recently been published and are available to purchase. Other therapy areas will be launched later in the year, including Ankylosing spondylitis, Multiple sclerosis, NASH, Haemophilia and Psoriasis amongst others.

More detailed findings from the study can be provided from Mariel Metcalfe on

Click here to find out more information on our Living with reports »

Sign up to receive Rapport 
Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here » 


comments powered by Disqus